8-K 1 nextcure8k_04132020.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2020 
NextCure, Inc.
(Exact name of registrant as specified in charter) 

   
 
 
 
 
Delaware
  
001-38905
  
47-5231247
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 


9000 Virginia Manor Road, Suite 200
Beltsville, Maryland
  
20705
(Address of principal executive offices)
  
(Zip Code)

 (240) 399-4900
______________
 
Registrant’s telephone number, including area code

______________
 
(Former name or former address, if changed since last report.) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
◻
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
◻
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
◻
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
◻
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
NXTC
Nasdaq Global Select Market
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.

On April 13, 2020, NextCure, Inc. (the “Company”) issued a press release providing an update on the Company’s clinical trail activities due to the impact of the COVID-19 pandemic. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.
 
Description
     
99.1
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
     
 
 
NEXTCURE, INC.
  Date: April 13, 2020
 
 
 
 
/s/ Steven P. Cobourn
 
 
Steven P. Cobourn
 
 
Chief Financial Officer